BMS Makes Second Big Buy Of December, Pays $4.1bn For RayzeBio
Bristol Myers Squibb makes its entrance into the increasingly competitive space of radiopharmaceuticals with its latest purchase, just days after its $14bn Karuna buy.
Bristol Myers Squibb makes its entrance into the increasingly competitive space of radiopharmaceuticals with its latest purchase, just days after its $14bn Karuna buy.